Several companies are advancing treatments for anal cancer, including Merck (KEYTRUDA), BioMimetix (BMX-001), Novartis (KFA115), and Bicara Therapeutics (BCA101), among others. As immunotherapy ...

Anal cancer is relatively uncommon, accounting for approximately 2.5% of all gastrointestinal cancers. Nonetheless, its ...

Hillstar Bio, a leading biotechnology company focused on developing next-generation precision immunology therapies for autoimmune diseases, today announced the appointment of Maude Tessier, Ph.D., as ...

Advanz Pharma secures exclusive rights from Alvotech to commercialize three biosimilar candidates in Europe in addition to previously partnered programs; The agreement includes pr ...

Teva Pharmaceutical Industries Limited’s TEVA stock has risen 12.9% in a month. Teva’s stock mainly gained after it announced ...

Recursion Pharmaceuticals RXRX and Schrodinger SDGR are pioneering the use of artificial intelligence (AI) in drug discovery ...

Loomis Sayles, an investment management company, released its “Global Growth Fund” first quarter 2025 investor letter. A copy ...

Regulus filed a solicitation/recommendation statement on Schedule 14D-9 with the SEC, which includes, among other things, the recommendation of Regulus’s board of directors that Regulus’s stockholders ...

“At ASCO and EHA, we will present new data on these priority medicines as well as updates from our pipeline and our industry-leading radioligand therapy research.” Novartis will also highlight its US ...

According to DealPulse’s M&A database, which harnesses both AI and attorneys to digest the granular deal points of publicly announced transactions, Regulus is advised by Latham & Watkins LLP, while ...